Korean Celltrion Gears Up To Produce Biosimilar Herceptin, Remicade, Erbitux; Proposes Barter System In Developing Regions
This article was originally published in PharmAsia News
Executive Summary
SEOUL - "Celltrion is currently developing a total of nine blockbuster antibody therapeutic biosimilars, and we are preparing for the launch of three biosimilars for markets not protected with patent rights," Kim Yong-Joong, Celltrion's strategic planning assistant manager, told PharmAsia News
You may also be interested in...
Green Cross Teams Up With MacroGenics For Bio-better Of Roche's Herceptin
SEOUL - South Korea's Green Cross has signed an agreement with Rockville, Maryland-based MacroGenics to develop and sell the latter's modified anti-breast cancer monoclonal antibody MGAH22 in Korea. MGAH22 is a modified "bio-better" of Roche's oncology agent Herceptin (trastuzumab)
Green Cross Teams Up With MacroGenics For Bio-better Of Roche's Herceptin
SEOUL - South Korea's Green Cross has signed an agreement with Rockville, Maryland-based MacroGenics to develop and sell the latter's modified anti-breast cancer monoclonal antibody MGAH22 in Korea. MGAH22 is a modified "bio-better" of Roche's oncology agent Herceptin (trastuzumab)
Korea's Celltrion Banks On Increasing Profits Resulting From New Focus On Biosimilars
SEOUL - Biopharmaceutical firm Celltrion posted a record performance in the most recent quarter due to the company's shift in focus from contract manufacturing to producing biosimilars